Another clinical study investigating the incidence and risk factors for TLS in relapsed/refractory multiple myeloma treated with anti-B-cell maturation antigen CAR-T cell therapy reported a 17.1% incidence of TLS among 105 patients [27]. Here, TNFRSF17 is linked to Tumor Lysis Syndrome.